• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

扎伊尔金沙萨的恶性疟原虫:体外药物敏感性研究。

Plasmodium falciparum in Kinshasa, Zaire: in vitro drug susceptibility studies.

作者信息

Nguyen-Dinh P, Greenberg A E, Kabote N, Davachi F, Goussard B, Embonga B

机构信息

Division of Parasitic Diseases, Centers for Disease Control, Atlanta, Georgia 30333.

出版信息

Am J Trop Med Hyg. 1987 Sep;37(2):217-9. doi: 10.4269/ajtmh.1987.37.217.

DOI:10.4269/ajtmh.1987.37.217
PMID:3310676
Abstract

In June 1986, Plasmodium falciparum parasites were collected from 33 children presenting at the Mama Yemo Hospital in Kinshasa (Zaire) and were successfully tested in vitro by a 48-hr reinvasion test for their susceptibility to various antimalarial drugs. In vitro resistance to chloroquine was found in 82% of the isolates, a marked increase over findings obtained by the same technique 3 years ago in Kinshasa. In vitro chloroquine resistance was not associated with a history of previous drug intake. The inhibitory endpoints for quinine varied from 0.03 to 1 microM, and correlated with the chloroquine endpoints in the corresponding isolates (r = 0.64). Pyrimethamine resistance in vitro was demonstrated in 52% of the isolates tested.

摘要

1986年6月,从金沙萨(扎伊尔)耶莫妈妈医院就诊的33名儿童身上采集了恶性疟原虫,并通过48小时再侵袭试验对其对各种抗疟药物的敏感性进行了体外成功检测。在82%的分离株中发现了对氯喹的体外抗性,这比3年前在金沙萨用相同技术获得的结果有显著增加。体外氯喹抗性与既往用药史无关。奎宁的抑制终点在0.03至1微摩尔之间,并且与相应分离株中的氯喹终点相关(r = 0.64)。在所检测的分离株中,52%表现出对乙胺嘧啶的体外抗性。

相似文献

1
Plasmodium falciparum in Kinshasa, Zaire: in vitro drug susceptibility studies.扎伊尔金沙萨的恶性疟原虫:体外药物敏感性研究。
Am J Trop Med Hyg. 1987 Sep;37(2):217-9. doi: 10.4269/ajtmh.1987.37.217.
2
Compared response to chloroquine, fansidar, quinine, and quinidine slow release of infections with Plasmodium falciparum in the Kivu region of Zaire.比较氯喹、 Fansidar(复方磺胺多辛-乙胺嘧啶)、奎宁和奎尼丁缓释剂对扎伊尔基伍地区恶性疟原虫感染的疗效。
Acta Leiden. 1987;55:159-62.
3
In vivo and in vitro susceptibility to chloroquine of Plasmodium falciparum in Kinshasa and Mbuji-Mayi, Zaire.扎伊尔金沙萨和姆布吉-马伊地区恶性疟原虫对氯喹的体内和体外敏感性
Bull World Health Organ. 1985;63(2):325-30.
4
[Comparative efficacy of alternative treatments in Plasmodium falciparum infections in Zaire].[扎伊尔恶性疟原虫感染替代治疗方法的疗效比较]
Ann Soc Belg Med Trop. 1989 Mar;69(1):25-33.
5
Antimalarial drug response of Plasmodium falciparum from Zaria, Nigeria.来自尼日利亚扎里亚的恶性疟原虫对抗疟药物的反应。
Trans R Soc Trop Med Hyg. 1995 Jul-Aug;89(4):422-5. doi: 10.1016/0035-9203(95)90037-3.
6
Drug-resistant Plasmodium falciparum malaria in the eastern Transvaal.德兰士瓦省东部的抗药恶性疟原虫疟疾
S Afr Med J. 1994 Jul;84(7):394-5.
7
[In vivo response to chloroquine during the treatment of Plasmodium falciparum malaria in a suburban region of Kinshasa, Zaire].[在扎伊尔金沙萨郊区治疗恶性疟原虫疟疾期间对氯喹的体内反应]
Ann Soc Belg Med Trop. 1985;65 Suppl 2:123-35.
8
Intravenous quinine therapy of hospitalized children with Plasmodium falciparum malaria in Kinshasa, Zaire.
Am J Trop Med Hyg. 1989 Apr;40(4):360-4. doi: 10.4269/ajtmh.1989.40.360.
9
Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire.扎伊尔难民营中卢旺达患者体内恶性疟原虫对氯喹和乙胺嘧啶-磺胺多辛的敏感性
Trans R Soc Trop Med Hyg. 1995 Nov-Dec;89(6):654-6. doi: 10.1016/0035-9203(95)90431-x.
10
[Limits of the efficacy of chloroquine and sulfadoxine-pyrimethamine in Northern Abidjan (Cote d'Ivoire): Combined in vivo and in vitro studies].[氯喹和磺胺多辛-乙胺嘧啶在阿比让北部(科特迪瓦)疗效的局限性:体内和体外联合研究]
Sante. 2004 Oct-Dec;14(4):205-9.

引用本文的文献

1
Hospital-based surveillance of malaria-related paediatric morbidity and mortality in Kinshasa, Zaire.扎伊尔金沙萨基于医院的疟疾相关儿童发病率和死亡率监测。
Bull World Health Organ. 1989;67(2):189-96.
2
Treatment of malaria--1990.疟疾的治疗——1990年。
Drugs. 1990 Feb;39(2):160-89. doi: 10.2165/00003495-199039020-00002.